Abstract Library

#1812 Correlation of Plasma (p) and Urine (u) 5-HIAA Levels in Patients (pts) with Carcinoid Syndrome (CS) – Post-Hoc Analyses from the TELESTAR Study

Introduction: Telotristat ethyl (TE) is an oral tryptophan hydroxylase inhibitor in development for treating CS symptoms. During the double-blind treatment [DBT] period of the phase 3, 12-week, placebo-controlled TELESTAR study, TE was well tolerated and significantly reduced bowel-movement frequency and u5-HIAA levels compared with placebo (PBO) in NET patients with CS treated with a SSA.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Pavel M, Hörsch D, Hoffmanns P, Biran T, Houchard A,

Keywords: carcinoid syndrome, 5-HIAA, telotristat,

#1809 What Do We Know About Carcinoid Heart Disease? A Systematic Literature Review

Introduction: Carcinoid heart disease (CHD) is a life-threatening complication of carcinoid syndrome (CS).

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Ovcinnikova O

Authors: Ovcinnikova O, Marshall M, Bagnati F, Hoffmanns P, Taveau ,

Keywords: carcinoid heart disease, systematic literature review, outcomes,

#1806 Epidemiology of Carcinoid Heart Disease (CHD) in Patients (pts) with Carcinoid Syndrome (CS): A Systematic Literature Review

Introduction: CHD develops in the context of CS due to the exposure of high levels of vasoactive substances, such as serotonin.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Ovcinnikova O

Authors: Ovcinnikova O, Marshall M, Bagnati F, Hoffmanns P, Taveau C,

Keywords: carcinoid syndrome, heart disease, epidemiology, prevalence, mortality,